“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z

Summary

Vijay Pande left Andreessen Horowitz's roughly $4 billion biotech practice to launch the smaller AI‑native venture VZVC, and argues that biology is moving from a discovery to an engineering paradigm while emphasizing that open, shared datasets are essential for AI to transform medicine.

Market Context

The commentary suggests a potential increase in demand for AI compute and data‑infrastructure services that could benefit AI‑chip makers (e.g., Nvidia) and cloud providers, while also signaling longer‑term pressure on biotech firms to adopt AI‑driven drug‑discovery workflows; however, no immediate revenue or partnership details are provided, making the transmission mechanism speculative.

Key Drivers

• article reports Vijay Pande departed a16z's $4 billion biotech practice to start VZVC
• article states biology is shifting from a "discovery" science to an "engineering" one
• article highlights open, shared datasets as a prerequisite for AI to transform medicine

Risks

• article provides no concrete data on market size, partnerships, or timelines for AI adoption in biotech
• clinical trials remain "brutally expensive," potentially limiting the speed of AI‑driven drug development

Time Horizon

Medium Term